01:47 AM EDT, 09/23/2026 (MT Newswires) -- Roche (RO.SW) said Wednesday that once-monthly subcutaneous injection sefaxersen met the primary endpoint of a phase 3 study after it helped reduce proteinuria in adults with primary IgA nephropathy, a progressive kidney disease. Prespecified interim data from the late-stage Imagination study showed that sefaxersen demonstrated statistically significant and clinically meaningful proteinuria reduction at 37 weeks, compared with placebo. Proteinuria, or protein in the urine, is a sign of kidney damage. The drug candidate's safety and tolerability profile remained in line with previously reported data. The Swiss drugmaker plans to share the interim results with health authorities, while the study will continue to evaluate changes in patients' kidney function over two years.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.